

EVOTEC EXPANDS SUSTAINABLY AT DOROTHY CROWFOOT HODGKIN CAMPUS

- ▶ *EVOTEC INVESTS IN SUSTAINABLE OPERATIONS AT DOROTHY CROWFOOT HODGKIN CAMPUS*
- ▶ *EXPANSION TO FEATURE 125 NEW SCIENTIFIC JOBS*
- ▶ *STATE-OF-THE-ART FACILITY WILL REDUCE ANNUAL EMISSIONS BY 800 METRIC TONS OF CO₂ PER ANNUM*

Hamburg, Germany, 03 February 2022:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company plans to significantly invest in its site at Milton Park, named Dorothy Crowfoot Hodgkin Campus, to reduce the CO₂ emissions. The project will help to achieve the company's carbon neutral targets.

At Dorothy Crowfoot Hodgkin Campus, named in commemoration of the British Nobel Prize winning chemist, Evotec is investing in energy-efficient operating methods. Air source heat pumps will replace traditional gas boilers and electric coolers and a demand-based laboratory ventilation system will be introduced, as well as the installation of low energy lighting and appliances. The Company expects the plans will reduce emissions by approximately 800 metric tons of CO₂ per year, the equivalent of over 970,000 worth of smartphone batteries.

Dr Christophe Muller, Global Head of Business Development and Evotec's Site Head at Milton Park, said: "Our Dorothy Crowfoot Hodgkin Campus at Milton Park is one of Evotec's most important and fast-growing fully integrated research and development centres. We've expanded our facility presence at the Park by over 40% in the last three years and have in excess of 700 employees across all major scientific disciplines required to research and develop drugs. We're keen to ensure that sustainability is front and centre of what we do and have therefore invested in state-of-the-art heating and air flow technologies into our new developments at Milton Park. This will reduce our CO₂ emissions in line with our internal targets as well as making our site a great and inspirational place to work."

The fit-out of the firm's premises on the Park is set to be complete in Summer 2022 and will accommodate new state-of-the-art biology laboratories, as well as a conference centre, a range of collaborative workspaces and meeting rooms and a 100-seat restaurant for Evotec employees. To support its continued growth, Evotec will also be creating 125 new scientific jobs.

For further information, [please follow this link](#) to the press release from Milton Park.

ABOUT EVOTEC SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter [@Evotec](#) and [LinkedIn](#).

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.